Kiniksa Pharmaceuticals International (KNSA) Asset Utilization Ratio (2022 - 2026)
Kiniksa Pharmaceuticals International's (KNSA) quarterly Asset Utilization Ratio came in at 0.98 in Q2 2026, up 16.32% YoY from 0.84 in Q2 2025, and up 2.93% on a QoQ basis from 0.95 in Q1 2026.
Kiniksa Pharmaceuticals International (KNSA) Asset Utilization Ratio (2022 - 2026) Analysis & Trends
Kiniksa Pharmaceuticals International (KNSA) has 5 years of Asset Utilization Ratio data on file, last reported at 0.98 in Q2 2026.
- Quarterly Asset Utilization Ratio rose 16.32% year-over-year to 0.98 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 0.98 (up 16.32% YoY) and the FY2025 annual result came in at 1.01, up 31.83% from the prior year.
- Asset Utilization Ratio advanced to 0.98 in Q2 2026, from 0.95 in the prior quarter.
- In the past five years, Asset Utilization Ratio ranged from a high of 0.98 in Q2 2026 to a low of 0.02 in Q4 2022.
- A 5-year average of 0.56 and a median of 0.61 in 2024 frame the typical range for Asset Utilization Ratio.
- The widest YoY moves for Asset Utilization Ratio: up 2362.26% in 2023, down 84.9% in 2023.
- Tracing KNSA's Asset Utilization Ratio over 5 years: stood at 0.02 in 2022, then soared by 2362.26% to 0.54 in 2023, then jumped by 39.17% to 0.75 in 2024, then rose by 23.2% to 0.92 in 2025, then grew by 6.41% to 0.98 in 2026.
- The last three Asset Utilization Ratio figures came in at 0.98 (Q2 2026), 0.95 (Q1 2026), and 0.92 (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.08 Bn | 39.43 Bn | 2.15 Bn | 0.43 |
| 3 | Zoetis | 31.54 Bn | 29.87 Bn | 1.05 Bn | 0.63 |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn | 0.47 |
| 5 | United Therapeutics | 22.12 Bn | 19.46 Bn | 683.80 Mn | 0.45 |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 0.41 |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn | 0.66 |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | 0.37 |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | - |
| 10 | Kiniksa Pharmaceuticals International | 6.07 Bn | 5.54 Bn | 220.03 Mn | 0.98 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 0.98 |
| Mar 31, 2026 | 0.95 |
| Dec 31, 2025 | 0.92 |
| Sep 30, 2025 | 0.87 |
| Jun 30, 2025 | 0.84 |
| Mar 31, 2025 | 0.82 |
| Dec 31, 2024 | 0.75 |
| Sep 30, 2024 | 0.70 |
| Jun 30, 2024 | 0.64 |
| Mar 31, 2024 | 0.58 |
| Dec 31, 2023 | 0.54 |
| Sep 30, 2023 | 0.08 |
| Jun 30, 2023 | 0.15 |
| Mar 31, 2023 | 0.06 |
| Dec 31, 2022 | 0.02 |
| Sep 30, 2022 | 0.53 |
| Jun 30, 2022 | 0.41 |
| Mar 31, 2022 | 0.31 |